Claire Marie Porter is a reporter with The Cancer Letter. She joined the publication in 2024.
Before joining The Cancer Letter, Claire was a freelance health and science journalist with bylines in The Atlantic, Scientific American, The Washington Post, Undark Magazine, Popular Science, WIRED among other publications. She graduated with an M.S. in Journalism from Columbia University in 2020, where she received honors for her thesis "The Deadly Itch" on Intrahepatic Cholestasis of pregnancy.
She was a 2020 Society of Environmental Journalists grant recipient, and completed internships with Next City and National Public Radio.
She graduated from Temple University with a Bachelor’s degree in English in 2013.
Before joining The Cancer Letter, Claire was a freelance health and science journalist with bylines in The Atlantic, Scientific American, The Washington Post, Undark Magazine, Popular Science, WIRED among other publications. She graduated with an M.S. in Journalism from Columbia University in 2020, where she received honors for her thesis "The Deadly Itch" on Intrahepatic Cholestasis of pregnancy.
She was a 2020 Society of Environmental Journalists grant recipient, and completed internships with Next City and National Public Radio.
She graduated from Temple University with a Bachelor’s degree in English in 2013.
Clinical
New data indicate that, professional guidelines notwithstanding, doctors rarely address concerns about sexual health when they treat women with cancer.
In the Archives
As oncology contemplates the potential impact of a second Donald Trump term on cancer care and research, The Cancer Letter has compiled a list of guest editorials, news analyses, and data-driven reports that this magazine published during his first term.
Regulatory News
FDA’s cancer czar Richard Pazdur had a “silver anniversary” at the agency recently. So, he invited some guests—the commissioners he had reported to under the Democratic and Republican administrations.
Regulatory News
More than a month has passed since Hurricane Helene took out Baxter North Cove plant, which manufactured 1.5 million IV fluid bags per day, supplying 60% of the intravenous solutions nationwide.
Clinical
NCI has launched a second-generation precision medicine clinical trial called Myeloid Malignancies Molecular Analysis for Therapy Choice, or myeloMATCH, a trial focused on acute myeloid leukemia and myelodysplastic syndromes.
Ivan Borrello, medical director of the Myeloma, Bone Marrow Transplant and Cell Therapies Program at Tampa General Hospital’s Cancer Institute, watched as flood waters from Hurricane Helene heaved against a contraption called the AquaFence, which is, as the name suggests, a water-impermeable barrier made of marine-grade laminate and various metals that can withstand storm surges of up to 15 feet above sea level.
